Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma
Midatech Pharma PLC (AIM:MTPH) MTX110 Development for the Treatment of Glioma
Midatech Pharma PLC (AIM:MTPH) Proposed New Chairman – MTX110 Study to be Presented
Midatech Pharma (MTPH), an R&D biotechnology company, said that Rolf Stahel, Chairman and non-executive director, intends to retire after the company’s AGM on 20 June 2022.
Atlantic Lithium (AIM:ALL) Metallurgical Profiling Continues to Deliver
Metallurgical Profiling Continues to Deliver
Atlantic Lithium* (LON:ALL) 49p, Mkt Cap £283m – Ewoyaa project set to expand as visible spodumene is observed in new drilling
FLASH NOTE PDF
Atlantic Lithium Ltd (AIM:ALL) Expanded Drilling Programme at Ewoyaa, Ghana
Additional Drill Rigs Mobilised to Site
Atlantic Lithium Ltd (AIM:ALL) Corporate Update – Response to Media Articles
Atlantic Lithium Limited (AIM: ALL, OTC: ALLIF, “Atlantic Lithium” or the “Company”), the African focused lithium exploration and development company, notes recent media articles referring to a potential investment in
Atlantic Lithium (AIM:ALL) Corporate Update – Board Appointment – Len Kolff
Board Appointment
Atlantic Lithium Ltd (AIM:ALL) Ewoyaa Mineral Resource Estimate Up 42% to 30.1Mt
Ewoyaa Lithium Resource Increases by a further 42% to 30.1Mt @ 1.26% Li2O
Atlantic Lithium Ltd (ALL.L) Further Lithium Infill Drilling Results, Ghana
Atlantic Lithium Limited (AIM: ALL, OTC: ALLIF, “Atlantic Lithium” or the “Company”), the fully-funded African focussed lithium exploration and development company on track to become West Africa’s first lithium producing
Cadence Minerals PLC (KDNC.L) Macarthur Moonshine Geotechnical Drill Programme
Macarthur Minerals (TSX-V: MMS, ASX: MIO) Lake Giles Feasibility Study Update. Macarthur to commence geotechnical drill programme at Moonshine to support mine planning for flagship magnetite project.
Futura Medical PLC (FUM.L) Notice of AGM and Annual Report
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused
